Owlstone Medical, the global leader in Breath Biopsy® for applications in early disease detection and precision medicine, today announced recruitment of the first patient into its EVOLUTION Phase 2 clinical trial following successful achievement of key safety and proof of concept milestones in Phase 1.
Exclusive: Strand lays off 18% of staff as its first mRNA therapies head into the clinic
Less than a week after announcing that regulators have greenlit the first tests of its tumor-busting mRNA therapy, Strand Therapeutics has laid off roughly 18%